Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Plerixafor in Diabetic Wound Healing
NCT02790957 · Gian Paolo Fadini · PHASE2 · terminated · last registry update 2019-12-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Safety reasons” | – | Registry record, Gian Paolo Fadini |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-10-30Results posted on the registry: Children's Hospital Medical Center, Cincinnati, AMD3100 (NCT00479115)
- 2020-10-20Also stopped (terminated): Washington University School of Medicine, Fludarabine + Busulfan (NCT02750254)
- 2020-09-07Also stopped (withdrawn): Massachusetts General Hospital, AMD3100 + Pembrolizumab (NCT04058145)
- 2020-07-24Also stopped (withdrawn): Jonsson Comprehensive Cancer Center, Aldesleukin + Cellular Therapy (NCT03506802)
- 2020-04-20Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Plerixafor (NCT03226691)
- 2020-03-13Results posted on the registry: Washington University School of Medicine, Selinexor + Cladribine (NCT02416908)
- 2020-03-03Phase 3 first posted: Genetix Biotherapeutics Inc., bb1111 (NCT04293185)
- 2020-03-02Also stopped (terminated): Weill Medical College of Cornell University, Plerixafor (NCT03277209)
- 2020-02-28Results posted on the registry: Que Oncology, oral capsule of Q-122 (NCT04080297)
- 2019-12-17Results posted on the registry: Weill Medical College of Cornell University, bortezomib (Velcade) + cyclophosphamide (NCT01146834)
- 2019-12-11Also stopped (withdrawn): University of Maryland, Baltimore, Neupogen + Plerixafor (NCT02682953)
- 2019-08-28Also stopped (terminated): M.D. Anderson Cancer Center, Plerixafor + Clofarabine (NCT01160354)
- 2019-06-27Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Preparative regimen (NCT04000698)
- 2019-06-21Phase 3 first posted: X4 Pharmaceuticals, Mavorixafor + Placebo (NCT03995108)
- 2019-06-14Results posted on the registry: Case Comprehensive Cancer Center, plerixafor + filgrastim (NCT01408043)
- 2019-06-14Also stopped (terminated): Case Comprehensive Cancer Center, plerixafor + filgrastim (NCT01408043)
- 2019-05-10Results posted on the registry: M.D. Anderson Cancer Center, Plerixafor + Clofarabine (NCT01160354)
- 2019-04-23Results posted on the registry: M.D. Anderson Cancer Center, Filgrastim + Plerixafor (NCT01818284)
- 2019-03-15Results posted on the registry: Memorial Sloan Kettering Cancer Center, lenalidomide and dexamethasone (NCT00807599)
- 2019-01-18Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Burixafor Hydrobromide + Docetaxel (NCT02478125)
- 2018-12-28Results posted on the registry: Fred Hutchinson Cancer Center, Carmustine + Filgrastim (NCT00669669)
- 2018-12-24Phase 3 first posted: Spexis AG, Eribulin + Balixafortide (NCT03786094)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision